Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Using tissue cell culture to make a protein or polypeptide
Reexamination Certificate
2010-02-12
2011-12-06
Ouspenski, Ilia (Department: 1644)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Using tissue cell culture to make a protein or polypeptide
Reexamination Certificate
active
08071336
ABSTRACT:
Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases.
REFERENCES:
patent: 6506559 (2003-01-01), Driver et al.
patent: 6602684 (2003-08-01), Umaña et al.
patent: 7700321 (2010-04-01), McPherson et al.
patent: 2003/0124653 (2003-07-01), Canfield
patent: 2003/0175969 (2003-09-01), Beliard et al.
patent: 2004/0228856 (2004-11-01), Presta
patent: 2007/0092521 (2007-04-01), McPherson et al.
patent: 1176195 (2002-01-01), None
Bosch et al., “The mannosidase inhibitors 1-deoxymannojirimycin and swainsonine have no effect on the biosynthesis and infectivity ofRous sarcomavirus,”Virology143:342-346 (1985).
Boyd et al., “The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H,”Mol. Immunol. 32:1311-1318 (1995).
Butters et al. “Novel mannosidase inhibitors probe glycoprotein degradation pathways in cells,”Glycoconj. J., Epub., 8 pages (Feb. 21, 2009).
Crispin et al., “Disruption of α-mannosidase processing induces non-canonical hybrid-type glycosylation,”FEBS Letters581:1963-1968 (2007).
Crispin et al., “Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GIcNAc transferase I-independent fucosylation pathway,”Glycobiology16:748-756 (2006).
Elbein et al., “Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I,”J. Biol. Chem. 265:15599-15605 (1990).
Elbein et al., “The pyrrolidine alkaloid, 2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine, inhibits glycoprotein processing,”J. Biol. Chem. 259(20):12409-12413 (1984).
Fleet et al., “Design synthesis and preliminary evaluation of a potent-mannosidase inhibitor: 1,4-dideoxy-1,4-imino-D-mannitol,”J. Chem. Soc. Chem. Commun. 1240-1241 (1984).
Gergely et al., “Fc receptors on lymphocytes and K cells,”Biochem. Soc. Trans. 12(5):739-743 (1984).
Hettkamp et al., “Purification by affinity chromatography of glucosidase I, an endoplasmic reticulum hydrolase involved in the processing of asparagine-linked oligosaccharides,”Eur. J. Biochem. 142(1):85-90 (1984).
Holliger et al., “Engineered antibody fragments and the rise of single domains,”Nature Biotech. 23:1126-1136 (2005).
International Search Report for PCT/US2006/060113 dated Aug. 9, 2007.
Kanda et al., “Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three differentN-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types,”Glycobiology17(1):104-118 (2006).
Kaushal et al., “Selective inhibition of glycoprotein-processing enzymes. Differential inhibition of glucosidases I and II in cell culture,”J. Biol. Chem. 263(33):17278-17283 (1988).
Ko et al., “Function and glycosylation of plant-derived antiviral monoclonal antibody,”PNAS100:8013-8018 (2003).
Köhler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature256:495-497 (1975).
Kumpel et al., “Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity,”Hum. Antibodies Hybridomas5:143-151 (1994).
Legler et al., “Synthesis of 5-amino-5-deoxy-D-mannopyranose and 1,5-dideoxy-1,5-imino-D-mannitol, and inhibition of alpha- and beta-D-mannosidases,”Carbohydr. Res. 128:61-72 (1984).
Longmore et al., “Product-identification and substrate-specificity studies of the GDP-L-fucose:2-acetamido-2-deoxy-beta-D-glucoside (FUC goes to Asn-linked GIcNAc) 6-alpha-L-fucosyltransferase in a Golgi-rich fraction from porcine liver,”Carbohydrate Res. 100:365-392 (1982).
Lund et al., “Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I,”Eur. J. Biochem. 267:7246-7257 (2000).
Molyneux et al., “Australine, a novel pyrrolizidine alkaloid glucosidase inhibitor fromCastanospermum australe,” J. Nat. Prod. 51:1198-1206 (1988).
Nose et al., “Inhibition of Processing of Asparagine-linked Carbohydrate Chains on IgG2a by Using Swainsonine has No Influence Upon Antibody Effector Functions In Vitro,”The J. Immunol. 145:910-914 (1990).
Palmarzyk et al., “1,4-Dideoxy-1,4-imino-D-mannitol inhibits Glycoprotein Processing and Mannosidase,”Arch. Biochem. Biophys. 243:35-45 (1985).
Pan et al., “Castanospermine Inhibits the Processing of the Oligosaccharide Portion of the Influenza Viral Hemagglutinin,”Biochemistry22:3975-3984 (1983).
Ravetch et al., “IgG Fc receptors,”Annu. Rev. Immunol. 9:457-92 (1991).
Rothman et al., “Antibody-Dependent Cytotoxicity Mediated by Natural Killer Cells is Enhanced by Castanospermine-Induced Alterations of IgG Glycosylation,”Mol. Immunol. 26:1113-1123 (1989).
Sarmay et al., “Ligand inhibition studies on the role of Fc receptors in antibody-dependent cell-mediated cytotoxicity,”Mol. Immunol. 21:43-51 (1984).
Segal et al., “Bispecific antibodies in cancer therapy,”Curr. Opin. Immunol. 11:558-562 (1999).
Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,”J. Biol. Chem. 276:6591-6604 (2001).
Shields et al., “Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity,”J. Biol. Chem. 277:26733-26740 (2002).
Shinkawa et al., “The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity,”J. Biol. Chem. 278:3466-3473 (2003).
Sondermann et al., “The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex,”Nature406:267-273 (2000).
Stanley et al., “Chinese hamster ovary cells selected for resistance to the cytotoxicity of phytohemagglutinin are deficient in a UDP-N-acetylglucosamine—glycoprotein N-acetylglucosaminyltransferase activity,”PNAS72(9):3323-3327 (1975).
Teillaud, “Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges,”Expert Opin. Biol. Ther. 5(Suppl. 1):S15-S27 (2005).
Umana et al., “Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity,”Nature Biotech. 17:176-180 (1999).
Weikert et al., “Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins,”Nature Biotech. 17:1116-1121 (1999).
Wright et al., “Effect of C2-Associated Carbohydrate Structure on Ig Effector Function: Studies with Chimeric Mouse-Human IgG1 Antibodies in Glycosylation Mutants of Chinese Hamster Ovary Cells,”J. Immunol.160:3393-3402 (1998).
Zhu et al., “Production of human monoclonal antibody in eggs of chimeric chickens,”Nature Biotech. 23:1159-1169 (2005).
Edmunds Tim
McPherson John M.
Zhou Qun
Finnegan Henderson Farabow Garrett & Dunner LLP
Genzyme Corporation
Ouspenski Ilia
LandOfFree
Antibody-based therapeutics with enhanced ADCC activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody-based therapeutics with enhanced ADCC activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody-based therapeutics with enhanced ADCC activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254907